This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n8https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n14http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Brexucabtagene_autoleucel
rdf:type
wikidata:Q8386 owl:Thing n14:ChemicalObject dbo:Drug dbo:ChemicalSubstance
rdfs:label
Brexucabtagene autoleucel
rdfs:comment
Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL). The most common side effects include serious infections, low blood cell counts and a weakened immune system. The most common side effects for the treatment of ALL include fever, CRS, hypotension, encephalopathy, tachycardias, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting.
dcterms:subject
dbc:Orphan_drugs dbc:Gene_therapy dbc:Gilead_Sciences dbc:Cancer_treatments dbc:Breakthrough_therapy
dbo:wikiPageID
64640677
dbo:wikiPageRevisionID
1122713393
dbo:wikiPageWikiLink
dbr:Gene_therapy dbr:B-cell dbr:Acute_lymphoblastic_leukemia dbr:T_cell dbr:Boxed_warning dbc:Orphan_drugs dbc:Gilead_Sciences dbr:Accelerated_approval_(FDA) dbr:Chimeric_antigen_receptor_T_cell dbr:Non-Hodgkin's_lymphoma dbr:Mantle_cell_lymphoma dbc:Gene_therapy dbr:Axicabtagene_ciloleucel dbr:Intravenous_therapy dbr:Orphan_drug dbr:Food_and_Drug_Administration dbr:Cytokine_release_syndrome dbc:Cancer_treatments dbc:Breakthrough_therapy dbr:Priority_review dbr:Breakthrough_therapy dbr:Risk_Evaluation_and_Mitigation_Strategies
owl:sameAs
n8:D4QY1 wikidata:Q97704053
dbp:wikiPageUsesTemplate
dbt:Short_description dbt:Portal_bar dbt:ClinicalTrialsGov dbt:Infobox_drug dbt:Use_American_English dbt:Drugs.com dbt:Reflist dbt:Use_dmy_dates dbt:Cite_journal
dbp:atcPrefix
None
dbp:drugbank
DB15699
dbp:kegg
D11880
dbp:legalUs
Rx-only
dbp:pregnancyCategory
Not recommended
dbp:routesOfAdministration
dbr:Intravenous_therapy
dbp:synonyms
KTE-X19
dbp:tradename
Tecartus
dbp:unii
4
dbo:abstract
Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL). The most common side effects include serious infections, low blood cell counts and a weakened immune system. The most common side effects for the treatment of ALL include fever, CRS, hypotension, encephalopathy, tachycardias, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting. Brexucabtagene autoleucel is a chimeric antigen receptor T cell therapy and is the first cell-based gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of mantle cell lymphoma. Brexucabtagene autoleucel was approved for medical use in the United States in July 2020, and in the European Union in December 2020.
dbp:dailymedid
Brexucabtagene_autoleucel
dbp:legalCa
Rx-only
dbp:legalEu
Rx-only
dbp:licenceUs
Tecartus
dbp:pregnancyAu
C
prov:wasDerivedFrom
wikipedia-en:Brexucabtagene_autoleucel?oldid=1122713393&ns=0
dbo:wikiPageLength
12975
dbo:alternativeName
Tecartus
dbo:drugbank
DB15699
dbo:fdaUniiCode
4MD2J2T8SJ
dbo:kegg
D11880
foaf:isPrimaryTopicOf
wikipedia-en:Brexucabtagene_autoleucel